Bacteria Have an Immune System. Scientists Just Found Its On Switch.

When a virus infects a bacterium, the bacterium's immune system usually waits for a piece of viral genetic material before switching on. New work in Science shows there is a second trigger, and the virus itself steps on it.

The discovery, from the lab of Sam Hobbs at the University of Utah Health, shows that a phage protease, an enzyme the virus uses to assemble new viral particles, also cleaves a host sensor protein. That cleavage flips on CBASS, one of the most common bacterial antiviral defenses. The finding, posted in late September on bioRxiv and now out in Science, defines a trigger that is distinct from the well-known pathway that senses viral nucleic acid to activate human cGAS-STING immunity.

"This is a new mechanism for how these host proteins get activated, distinct from pathways that sense viral genetic material," Hobbs told reporters, describing it as his lab's "total eureka moment."

CBASS stands for cyclic oligonucleotide-based antiphage signaling system. It works by producing small signaling molecules that, when the bacterium detects a viral threat, activate an effector that kills the infected cell before the virus can replicate. The abortive self-sacrifice is what stops the spread. The Kranzusch lab at Harvard Medical School has mapped much of the system's biochemistry, including the structure of the host sensor proteins known as CD-NTases, or cGAS/DncV-like nucleotidyltransferases. Until now, the central puzzle was how the sensor knew the cell was under attack in the first place.

The Utah team now argues that the virus trips the wire itself. Phage prohead proteases, the enzymes that cut viral coat proteins so the virus can finish assembling its shell, also cut the bacterial CD-NTase sensor. That cut activates the enzyme to produce the cyclic signaling molecules that CBASS uses to call the kill. In lab tests, mutating the cleavage site on the sensor blocked CBASS activation; mutating the protease on the phage blocked the same activation. The team argues the mechanism is widespread precisely because the prohead protease is shared across the tailed phages that infect most bacteria, while CD-NTases are among the most common immune sensors in bacterial genomes. The two pieces are essentially always present in organisms that run CBASS.

The conservation matters beyond bacteria. CD-NTases are a bacterial cousin of human cGAS, the sensor that calls the immune system to viral DNA. Finding that a viral protease, not just viral DNA, can switch a CD-NTase on suggests a route by which virus-encoded proteins might also nudge the human pathway. That remains a hypothesis, the Utah Health release notes; the paper itself does not extend the claim into human cells.

As standard antibiotics have lost ground to resistant infections, doctors and biotech firms have revived the idea of using phages, viruses that specifically infect bacteria, as treatments. The obstacle is that bacteria are not passive hosts. CBASS and other immune systems can kill the infected cell before the therapy can do its work. Knowing the exact molecular switch that turns CBASS on gives phage designers a concrete target: either evade the cleavage, or pick phages whose proteases the bacterium's CD-NTase cannot recognize.

News-Medical's coverage frames the result as groundwork rather than product. The Utah release is careful with the same hedge: the finding "can pave the way" for better phage therapies, not deliver one. Clinical phage therapy remains a small, regulator-by-regulator field, and the new mechanism is one design input among many, not a near-term cure.

What the paper does deliver is a sharper picture of what scientists now know they did not know. CBASS activation had a known nucleic-acid trigger and a known structural machine. It now has a second, protease-driven trigger, wired into the most conserved part of the phage life cycle. For builders trying to outflank bacterial immunity, the map just got one more contour line.